News
Taking AIM1 at prostate cancer invasion and metastasis
- Details
- Created on 08 November 2017
- Written by Super User
Progression to metastatic disease is the major cause of prostate cancer related death. Loss or mislocalization of AIM1 (aka CRYBG1), which regulates cytoskeletal remodeling, was shown to promote prostate cancer invasion and metastases. Read more about it in Haffner et al, Nat Commun, 2017. See also the press release and some of the media coverage of the findings.
Heart drug found to have activity in prostate cancer
- Details
- Created on 16 December 2011
- Written by Srinivasan (Vasan) Yegnasubramanian
Our multidisciplinary team used both laboratory and epidemiological approaches to uncover a potential application of the heart drug digoxin in prostate cancer prevention and/or therapy. Read about it in the April issue of Cancer Discovery. This work has been covered by several press sources, e.g., ScienceDaily (Apr. 3, 2011): Heart Drug Cuts Prostate Cancer Risk, Holds Potential for Therapeutic Use.
Hydroxymethylcytosine in normal and cancer tissues
- Details
- Created on 15 October 2011
- Written by Srinivasan (Vasan) Yegnasubramanian
Our research team recently showed that 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments in normal tissues and profoundly reduced in multiple human cancers. These findings were published in the August 2011 issue of Oncotarget, and has been covered by multiple independent epigenetics blogs including the epiexperts.com.
News